ArticleThe American journal of pathology2011
Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer.
Article in The American journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.British journal of cancer · 2014Trial
- Flow-induced Shear Stress Confers Resistance to Carboplatin in an Adherent Three-Dimensional Model for Ovarian Cancer: A Role for EGFR-Targeted Photoimmunotherapy Informed by Physical Stress.Journal of clinical medicine · 2020Article
- Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning.Nature medicine · 2018Article
- Downregulation of EGFR in hypoxic, diffusion-limited areas of squamous cell carcinomas of the head and neck.British journal of cancer · 2016Article
- Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.Cancer research and treatment · 2015Article
- Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays.Science signaling · 2015Article
- Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.Urologic oncology · 2014Review
- Relationship between uptake of a radioiodinated quinazoline derivative and radiosensitivity in non-small cell lung cancer.American journal of nuclear medicine and molecular imaging · 2014Article
- Detecting EGFR alterations in clinical specimens-pitfalls and necessities.Virchows Archiv : an international journal of pathology · 2013Article
- A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy.Journal of personalized medicine · 2013Article
- Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Article
- Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.BMC cancer · 2012Article
- Emerging personalized approaches for the management of advanced urothelial carcinoma.Expert review of anticancer therapy · 2012Review
- The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities.Molecular oncology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Challenges in measurement of epidermal growth factor receptor (EGFR) protein expression have led to conflicting data on its prognostic value and discontinuation of its use for prediction of response. Herein is described a quantitative standardized assay for EGFR and its use in a series of retrospective cohorts of patients with non-small cell lung cancer (NSCLC). The AQUA technology of quantitative immunofluorescence was used in conjunction with Western blot analysis to calculate the absolute concentration of EGFR in two independent NSCLC cohorts (170 from Yale New Haven Hospital and 335 from Sotiria and Patras Hospitals in Greece). EGFR and mutated EGFR were measured using D38B1 antibody and two mutation-specific antibodies. All patients positive or borderline for mutation-specific antibody were genotyped. A threshold for reproducible detection of EGFR was defined as 0.85 ng/μg total protein. EGFR expression demonstrated no prognostic value in either cohort. The mutation rate was 1.79% in the Yale cohort, and 1.52% in the Sotiria/Patras cohort, with no antibody detection-based false-positive cases. No mutations were detected for EGFR concentrations <1.46 ng/μg total protein. In summary, accurate measurement of EGFR still shows no prognostic value in NSCLC. In these two population-based cohorts, the antibody-based EGFR mutation rate was lower than has been frequently reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.